They dont have to worry about money. They got the Big Cheese :)
Pfizer(PFE) has licensed a stem cell therapy for inflammatory bowel disease from Athersys(ATHX).
ATHX Athersys will received $6 million upfront from Pfizer and is eligible for another $105 million in future milestone payments. Pfizer is paying the costs to develop the stem cell therapy, known as MultiStem, for inflammatory bowel disease.
MultiStem is made from stem cells obtained from the bone marrow of healthy, adult donors.
Pfizer will pay royalties to Athersys if MultiStem is approved for sale. Athersys retains the rights to develop MultiStem in various other indications
"Pump-a-doodle-doo...This Co. is mostly hype, and IMHO it is still way over-priced"...my first post regarding ATHX (Aug 25/10).
I outsmarted them all - the paid pumpers, the stupid analysts, the insiders who bought shares at much higher levels...little ol Natezanny was right all along. Read it and weep suckers, read it and weep!
I'm outta here for good...but I'll be watching for the pumping hoards just in case they get too cheeky ;)
P.S. Where's Kou Kou Fax? ROTFLMAO...L@@K AT YOU KOU KOU L@@K AT YOU, CAUSE I'M LAUGHING AT YOU!!!!! Yeah Baby Yeah.